세계의 흑폐증 시장 보고서(2025년)

Black lung disease, also known as coal workers' pneumoconiosis (CWP), is a chronic and potentially fatal lung condition primarily affecting coal miners and those exposed to coal dust. This ailment is characterized by the accumulation of coal dust particles in the lungs, leading to inflammation, scarring, and damage to lung tissues.

The disease is categorized into simple coal workers' pneumoconiosis, complicated coal workers' pneumoconiosis, and other forms. Simple CWP, often referred to as simple black lung disease, arises from prolonged exposure to coal dust. Treatment options encompass oxygen therapy, bronchodilators, lung transplant, stem cell therapy, and other interventions. Diagnosing the condition involves procedures like biopsy, various imaging techniques, full blood count analysis, pulmonary function tests, physical examination, among others. These diagnostic and treatment approaches are employed across a range of healthcare settings, including hospitals, clinics, research institutions, diagnostic centers, and laboratories.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The black lung disease market research report is one of a series of new reports from The Business Research Company that provides black lung disease market statistics, including black lung disease industry global market size, regional shares, competitors with a black lung disease market share, detailed black lung disease market segments, market trends and opportunities and any further data you may need to thrive in the black lung disease industry. This black lung disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The black lung disease market size has grown rapidly in recent years. It will grow from $9.66 billion in 2024 to $10.92 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to coal mining industry growth, awareness and education, compensation and benefits, legislative and legal developments.

The black lung disease market size is expected to see rapid growth in the next few years. It will grow to $19.23 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to public health initiatives, medical advancements, increasing treatment options, advocacy and support organizations. Major trends in the forecast period include advanced diagnostic techniques, research and prevention, healthcare access, technological advancements.

The forecast of 15.2% growth over the next five years remains unchanged from the previous projection for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. pulmonology care by inflating prices of portable oxygen concentrators and pulmonary rehabilitation equipment developed in Germany and Japan, resulting in delayed interventions for coal miners and higher respiratory therapy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growth of the black lung disease market is expected to be fueled by rising mining activities. Mining involves extracting minerals, ores, and other geological materials from the earth's crust, which can expose workers to coal mine dust. This dust, filled with harmful carbon particles, poses a significant health risk to coal miners and can lead to black lung disease. For example, in July 2023, the International Energy Agency (IEA), an intergovernmental organization based in France, reported a substantial increase in critical mineral production, which rose by 30% to $41 billion in 2022, following a 20% increase in 2021. Over the past five years, demand for critical minerals has surged, with lithium usage tripling and cobalt demand rising by 70%. Consequently, the expansion of mining activities is contributing to the growth of the black lung disease market.

The escalating prevalence of tuberculosis is anticipated to drive the growth of the black lung disease market. Tuberculosis, caused primarily by Mycobacterium tuberculosis, is an airborne bacterial infection transmitted when an infected person coughs or sneezes. It manifests with symptoms like coughing, fever, weight loss, and fatigue. The increasing incidence of tuberculosis is linked to the growth of black lung disease, as individuals with TB face a higher risk of developing black lung disease and are more likely to be exposed to coal dust. For instance, in March 2023, the Centers for Disease Control and Prevention reported 8,300 cases of tuberculosis in the US in 2022, up from 7,874 cases in 2021. Thus, the rising prevalence of tuberculosis is a significant driver behind the growth of the black lung disease market.

The growth of the black lung disease market is significantly bolstered by government funding initiatives. These initiatives involve the allocation of financial resources by government bodies, often at federal, state, or local levels, to support a range of activities, programs, projects, and organizations that serve public interests or fulfill specific government objectives. One crucial area of focus for such funding is the protection of coal miners from black lung disease. For instance, in September 2022, according to the US Department of Labor Blog, a US-based government authority, funding for miners with black lung disease was permanently extended with the Inflation Reduction Act of 2022. This act has provided essential and permanent funding for miners and their families affected by black lung disease, ensuring federal black lung benefits. As a result, government funding initiatives play a pivotal role in driving both the black lung disease market and the welfare of miners.

In June 2022, Bristol Myers Squibb, a prominent US-based pharmaceutical company, successfully acquired Turning Point Therapeutics, further solidifying its position in the field of oncology and black lung disease treatment. This strategic move allows Bristol Myers to integrate a cutting-edge, late-stage precision oncology asset into its already robust oncology portfolio. Turning Point Therapeutics, a US-based pharmaceutical company, is currently in the process of developing a drug with potential applications in the treatment of black lung disease.

Major companies operating in the black lung disease market are Pfizer Inc., Johnson and Johnson, Siemens AG, General Electric, F. Hoffmann-La Roche AG, Merck and Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca PLC, Melinta Therapeutics LLC, GlaxoSmithKline PLC, Medtronic PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Toshiba Corporation, Koninklijke Philps N.V., Mayo Clinic, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Lab India Pvt. Ltd., Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Lupin Limited.

North America was the largest region in the black lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in black lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the black lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The black lung disease market includes revenues earned by entities by providing pulmonary rehabilitation (PR), medical services and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Black Lung Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on black lung disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for black lung disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The black lung disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Simple Coal Worker's Pneumoconiosis; Complicated Coal Worker's Pneumoconiosis; Other Types
• 2) By Treatment: Oxygen Therapy; Bronchodilators; Lung Transplant; Stem Cell Therapy; Other Treatment
• 3) By Diagnosis: Biopsy; Imaging; Full Blood Count; Pulmonary Or Lung Function Tests; Physical Examination; Other Diagnosis
• 4) By End Users: Hospitals And Clinics; Research Organizations And Academic Institutes; Diagnostic Centers And Labs; Other End Users
• Subsegments:
• 1) By Simple Coal Worker's Pneumoconiosis: Asymptomatic Simple Pneumoconiosis; Symptomatic Simple Pneumoconiosis
• 2) By Complicated Coal Worker's Pneumoconiosis: Progressive Massive Fibrosis (PMF); Complicated Pneumoconiosis With Respiratory Symptoms
• 3) By Other Type: Mixed Dust Pneumoconiosis; Other Related Respiratory Diseases
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson; Siemens AG; General Electric; F. Hoffmann-La Roche AG; Merck and Co. Inc.; Bayer AG; Novartis AG; Sanofi S.A.; AstraZeneca plc; Melinta Therapeutics LLC; GlaxoSmithKline plc; Medtronic plc; Eli Lilly and Company; Boehringer Ingelheim International GmbH; Toshiba Corporation; Koninklijke Philps N.V.; Mayo Clinic; Baxter International Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Perrigo Lab India Pvt. Ltd.; Aurobindo Pharma Limited; Hikma Pharmaceuticals plc; Lupin Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Black Lung Disease Market Characteristics

3. Black Lung Disease Market Trends And Strategies

4. Black Lung Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

• 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Black Lung Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Black Lung Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Black Lung Disease Market Growth Rate Analysis
• 5.4. Global Black Lung Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Black Lung Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Black Lung Disease Total Addressable Market (TAM)

6. Black Lung Disease Market Segmentation

• 6.1. Global Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Simple Coal Worker's Pneumoconiosis
• Complicated Coal Worker's Pneumoconiosis
• Other Types
• 6.2. Global Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oxygen Therapy
• Bronchodilators
• Lung Transplant
• Stem Cell Therapy
• Other Treatment
• 6.3. Global Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biopsy
• Imaging
• Full Blood Count
• Pulmonary Or Lung Function Tests
• Physical Examination
• Other Diagnosis
• 6.4. Global Black Lung Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Research Organizations And Academic Institutes
• Diagnostic Centers And Labs
• Other End Users
• 6.5. Global Black Lung Disease Market, Sub-Segmentation Of Simple Coal Worker's Pneumoconiosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Asymptomatic Simple Pneumoconiosis
• Symptomatic Simple Pneumoconiosis
• 6.6. Global Black Lung Disease Market, Sub-Segmentation Of Complicated Coal Worker's Pneumoconiosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Progressive Massive Fibrosis (PMF)
• Complicated Pneumoconiosis With Respiratory Symptoms
• 6.7. Global Black Lung Disease Market, Sub-Segmentation Of Other Type, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mixed Dust Pneumoconiosis
• Other Related Respiratory Diseases

7. Black Lung Disease Market Regional And Country Analysis

• 7.1. Global Black Lung Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Black Lung Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Black Lung Disease Market

• 8.1. Asia-Pacific Black Lung Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Black Lung Disease Market

• 9.1. China Black Lung Disease Market Overview
• 9.2. China Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Black Lung Disease Market

• 10.1. India Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Black Lung Disease Market

• 11.1. Japan Black Lung Disease Market Overview
• 11.2. Japan Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Black Lung Disease Market

• 12.1. Australia Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Black Lung Disease Market

• 13.1. Indonesia Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Black Lung Disease Market

• 14.1. South Korea Black Lung Disease Market Overview
• 14.2. South Korea Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Black Lung Disease Market

• 15.1. Western Europe Black Lung Disease Market Overview
• 15.2. Western Europe Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Black Lung Disease Market

• 16.1. UK Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Black Lung Disease Market

• 17.1. Germany Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Black Lung Disease Market

• 18.1. France Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Black Lung Disease Market

• 19.1. Italy Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Black Lung Disease Market

• 20.1. Spain Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Black Lung Disease Market

• 21.1. Eastern Europe Black Lung Disease Market Overview
• 21.2. Eastern Europe Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Black Lung Disease Market

• 22.1. Russia Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Black Lung Disease Market

• 23.1. North America Black Lung Disease Market Overview
• 23.2. North America Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Black Lung Disease Market

• 24.1. USA Black Lung Disease Market Overview
• 24.2. USA Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Black Lung Disease Market

• 25.1. Canada Black Lung Disease Market Overview
• 25.2. Canada Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Black Lung Disease Market

• 26.1. South America Black Lung Disease Market Overview
• 26.2. South America Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Black Lung Disease Market

• 27.1. Brazil Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Black Lung Disease Market

• 28.1. Middle East Black Lung Disease Market Overview
• 28.2. Middle East Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Black Lung Disease Market

• 29.1. Africa Black Lung Disease Market Overview
• 29.2. Africa Black Lung Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Black Lung Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Black Lung Disease Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Black Lung Disease Market Competitive Landscape And Company Profiles

• 30.1. Black Lung Disease Market Competitive Landscape
• 30.2. Black Lung Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Siemens AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. General Electric Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Black Lung Disease Market Other Major And Innovative Companies

• 31.1. Merck and Co. Inc.
• 31.2. Bayer AG
• 31.3. Novartis AG
• 31.4. Sanofi S.A.
• 31.5. AstraZeneca plc
• 31.6. Melinta Therapeutics LLC
• 31.7. GlaxoSmithKline plc
• 31.8. Medtronic plc
• 31.9. Eli Lilly and Company
• 31.10. Boehringer Ingelheim International GmbH
• 31.11. Toshiba Corporation
• 31.12. Koninklijke Philps N.V.
• 31.13. Mayo Clinic
• 31.14. Baxter International Inc.
• 31.15. Teva Pharmaceutical Industries Ltd.

32. Global Black Lung Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Black Lung Disease Market

34. Recent Developments In The Black Lung Disease Market

35. Black Lung Disease Market High Potential Countries, Segments and Strategies

• 35.1 Black Lung Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Black Lung Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Black Lung Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer